Arepanrix Kit
Product Images NDC 58160-742

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Arepanrix (NDC 58160-742). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Glaxosmithkline Biologicals Sa, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Arepanrix 10 Dose Carton (Arepanrix Spl Graphic 01)

Arepanrix 10 Dose Carton (Arepanrix Spl Graphic 01)
This text provides information about the influenza A (H5) monovalent vaccine called AREPANRIX. It explains how to combine the AS03 Adjuvant Component with the H5 Antigen Component to create the vaccine for people aged 6 months and older. The vaccine is administered via intramuscular injection in doses of 0.25 mL for ages 6 months through 17 years and 0.5 mL for 18 years and older. Each multiple-dose vial contains 5 mL of AREPANRIX. The package includes 10 vials of H5 Antigen Component and 10 vials of AS03 Adjuvant Component.*
FDA Label Image

H5 Antigen Vial Label (Arepanrix Spl Graphic 02)

H5 Antigen Vial Label (Arepanrix Spl Graphic 02)
This is a prescription medication for an Influenza A (H5) Monovalent Vaccine, Adjuvanted (AREPANRIX). It includes a vial containing the H5 Antigen Component, which should not be used alone. It is recommended to add 1 vial of AS03 Adjuvant Component to the H5 Antigen Component vial to form the vaccine. The dose is 0.25 mL for individuals aged 6 months through 17 years and 0.5 mL for individuals 18 years and older. Manf. by ID Biomedical Corporation of Quebec.*
FDA Label Image

As03 Vial Label (Arepanrix Spl Graphic 03)

As03 Vial Label (Arepanrix Spl Graphic 03)
This is a description of an adjuvant component labeled as AAS03, intended to be added to a vial of antigen component to create 10 doses of vaccine. The manufacturing company is GlaxoSmithKline Biologicals. This adjuvant should not be used alone and is designed to enhance the immune response when combined with the antigen component.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.